3World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland: World Health Organization, 1999.
4Lohmann T, Kellner K, Verlohren H J, et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults(LADA). Diabetologia, 2001, 44(8):1005
5Behme M T, Dupre J, Harris S B, et al. Insulin resistance in latent autoimmune diabetes of adulthood. Ann N Y Acad Sci, 2003,1005:374
6Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001,24(4):683
7Karvonen M, Viik-Kajander M, Moltchanova E, et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care, 2000,23(10):1516
8UK Prospective Diabetes Study(UKPDS)Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet,1998,352(9131):854
9Kobayashi T, Maruyama T, Shimada A, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent(type 1)diabetes mellitus. Ann N Y Acad Sci, 2002,958( ):117
10Clark R B, Bishop-Bailey D, Estrada-Hernandez T, et al. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol,2000,164(3):1364
2[1]Tuomi T, Groop LC, Zimmet PZ, et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes, 1993, 42:359-362
3[2]Juneja R, Palmer JP. Type 1.5 Diabetes: myth or reality?Autoimmunity, 1997, 29:65-83
4[3]World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications:report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland:World Health Organization, 1999
5[6]Carlsson A, Sundkvist G, Groop L, et al. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab,2000, 85:76-80
6[7]Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes, 1999, 48:150-157
7[8]Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24:683-689
8[9]Kobayashi T, Maruyama T, Shimada A, et al. Insulin intervention to preserve beta cells in slowly progressive insulindependent (type 1) diabetes mellitus. Ann NY Acad Sci, 2002, 958:117-130
9[10]Dubuquoy L, Bourdon C, Peuchmaur M, et al. Peroxisome proliferator activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease. Gastroenterol Clin Biol, 2000, 24:719-724
10[11]Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse:implications for human type 1 diabetes. Diabetes Metab Res Rev, 2002, 18:114-117
5Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 1998,15 : 539-553.
6Fourlanos S, Dotta F, Gre enbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabeto togia, 2005, 48: 2206-2212.
7Carlsson A, Sundkvist G, Groop L, et al. Insulin and glucagons secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab, 2000,85:76.
8Behme MT, Dupre J, Harris SB,et al. Insulin resistance in latent autoimmune diabetes of adulthood. Ann N Y Aead Sei, 2003, 1005 : 374-377.
9Muller G,Hant D,Punter J,et al. Differential interact in glimepiride with B cell sulfonylurea receptor. Biochim Biophys Acta, 2004, 1191(2) :267-277.
